Borderline personality disorder: identification, comorbidity, and emerging treatment opportunities
Мikhail L. Zobin
Neurology Bulletin June 14, 2025 DOI: 10.17816/nb677346 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective open study Peer reviewed |
|---|---|
| Sample size | 18 |
| Population | Patients with dual (borderline personality disorder + alcohol/cocaine use disorder) or triple (borderline personality disorder + alcohol/cocaine use disorder + depression) diagnosis |
| Intervention | Ketamine infusions |
| Dose | 0.5–0.75 mg/kg over 40 minutes |
| Duration | Three infusions over one week, followed by a booster session one month later |
| Keywords | Comorbidity Borderline personality disorder Clinical psychology Identification biology Personality disorders Psychotherapist |
| Key points | Preliminary results of ketamine therapy for patients with borderline personality disorder and comorbid substance use disorders and depression were comparable to the effectiveness of specialized psychotherapy. |
Abstract
This article analyses the diagnostic criteria for borderline personality disorder as defined in the 5th edition of Diagnostic and Statistical Manual of Mental Disorders and the 11th revision of International Classification of Diseases. The combination of categorical and dimensional diagnostic models improves its validity, which meets the needs of clinical practice. At the same time, the heterogeneity and persistent conceptual ambiguity of borderline personality disorder are emphasized. The phenomenology of comorbidity between borderline and addictive disorders is considered as overlapping symptoms that exacerbate overall clinical presentation. Challenges in diagnosing borderline personality disorder are noted when constitutional symptoms are masked by the consequences of psychoactive substance use. The article offers a brief overview of current approaches to the treatment of borderline personality disorder, highlighting the potential of ketamine therapy. The results of our own retrospective open study of 18 patients with dual (borderline personality disorder + alcohol/cocaine use disorder) and triple (borderline personality disorder + alcohol/cocaine use disorder + depression) diagnosis who received ketamine treatment are discussed. Patients received three ketamine infusions over one week (0.5–0.75 mg/kg over 40 minutes), followed by a booster session one month later. Preliminary results of treatment are discussed, which are quite comparable with the effectiveness of specialized psychotherapy. These findings suggest that ketamine therapy may offer a novel perspective on the traditionally pessimistic therapeutic outlook for borderline personality disorder.
Citations in the library
Cites 18
- Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial American Journal of Psychiatry December 5, 2017
- Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment December 1, 2002
- Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review BJPsych Open December 23, 2021
- Ketamine treatment for depression: a review Discover Mental Health April 15, 2022
- The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions Frontiers in Pharmacology February 21, 2018
and 13 more in the library